Latest Operational Costs News

Invion Limited has secured a pivotal FDA Orphan Drug Designation for its lead cancer drug INV043, bolstered its balance sheet with nearly $1.8 million in new funding, and progressed clinical trials targeting skin and anogenital cancers.

Jindalee Lithium is progressing its McDermitt Lithium Project with a proposed US SPAC listing, government backing, and an $8 million capital raise, positioning it as a key player in the US critical minerals landscape.

Hastings Technology Metals has completed a transformative joint venture with Wyloo for its Yangibana Rare Earths Project, eliminating $123 million in debt and divesting its gold portfolio to sharpen its rare earths focus.

Holista Colltech reported improved cash flow management and robust growth in its dietary supplements division for 3QFY25, while navigating ongoing legal challenges with ProImmune.

WA Kaolin Limited has reported a remarkable surge in sales volumes and revenue for the September 2025 quarter, driven by operational upgrades and expanding market reach. The company’s forward orders and product diversification signal robust growth ahead.

AVADA Group Limited reported a revenue increase in Q1 FY26 despite ending a major contract, alongside a significant reduction in operating cash outflows and ongoing debt repayments.

James Bay Minerals reports exceptional metallurgical testwork results from its Independence Project in Nevada, confirming over 95% gold recovery using conventional processing methods. The findings highlight the project's potential for cost-effective development of its high-grade skarn resource.

Thor Energy reported a transformative quarter with standout natural hydrogen and helium exploration results at its HY-Range Project, alongside significant asset sales that strengthen its financial position.

Geopacific Resources advances its Woodlark Gold Project with promising drilling results at Kamwak and a crucial mining lease extension, while strengthening strategic partnerships and progressing its feasibility study.

Far East Gold reports a productive September quarter with significant drilling results at its Idenburg Project, including a new high-grade discovery at North Bermol and an expanded pipeline of exploration targets.

Vectus Biosystems has signed a binding agreement to sell its VB4-P5 renal fibrosis compound to Canadian biotech XORTX Therapeutics, while actively pursuing licensing opportunities for its lead drug VB0004 and others, particularly in China.

CAQ Holdings reported a 7% drop in leasing revenue amid persistently high vacancy rates and cash flow pressures in the September 2025 quarter. The company is negotiating lease renewals and seeking debt facility extensions to sustain operations.